source
- Lilly and FDA clash over retatrutide classification as company nears submissionEli Lilly is preparing to file its obesity drug candidate retatrutide for approval while a legal dispute with the FDA over the drug's classification intensifies. The agency has concluded that reta…
- FDA approves Takeda's orexin drug for narcolepsy type 1Takeda has received FDA approval for its orexin agonist intended to treat narcolepsy type 1. The decision ends a closely watched commercial race to bring an orexin-based therapy to market. With a…